# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce cystic fibrosis
- describe symptoms and effects
- explain genetic cause
- discuss current treatments and limitations

## SUMMARY OF THE INVENTION

- introduce method of reducing ΔF508-CFTR ubiquitination
- describe NEDD8 therapeutic agent
- specify RNAi molecule and antisense oligonucleotide
- describe small molecule drug
- introduce FBXO2 therapeutic agent
- specify RNAi molecule and antisense oligonucleotide
- describe small molecule drug
- introduce SYVN1 therapeutic agent
- specify RNAi molecule and antisense oligonucleotide
- describe small molecule drug
- describe combination therapy
- specify AHSA1 therapeutic agent
- describe CFTR corrector and potentiator
- specify cell types and mammals
- describe treatment methods and administration

## DETAILED DESCRIPTION OF THE INVENTION

- motivate therapeutic strategies for cystic fibrosis
- describe CFTR biosynthetic pathway
- introduce methods of using therapeutic agents to treat cystic fibrosis
- describe NEDD8 therapeutic agents
- describe FBXO2 therapeutic agents
- describe SYVN1 therapeutic agents
- describe AHSA1 therapeutic agents
- describe CFTR correctors
- describe CFTR potentiators
- describe auxiliary compounds
- describe SIN3A therapeutic agents
- describe miR-138 mimic
- describe CFTR small molecule therapeutic agents
- describe pharmaceutically acceptable salts
- describe RNA interference (RNAi) molecules
- describe Dicer-substrate RNAs (DsiRNAs)
- describe short hairpin RNA (shRNA)
- describe artificial miRNA
- describe off-target toxicity
- define RNAi
- define suppressing
- define mutant protein
- define gene
- define nucleic acid
- define nucleotide sequence
- define isolated nucleic acid
- define functional RNA
- describe oligonucleotide modifications for stability
- introduce sugar-modified ribonucleotides
- introduce backbone-modified ribonucleotides
- introduce nucleobase-modified ribonucleotides
- describe combination of modifications
- introduce α-anomeric nucleic acid molecules
- introduce peptide nucleic acids
- describe PNA-DNA chimeras
- introduce morpholino oligonucleotides
- introduce Locked Nucleic Acids
- describe conjugation of oligonucleotides to other molecules
- specify DsiRNA composition
- describe target RNA specificity
- define sequence identity
- define sequence identity
- describe determination of sequence complementarity
- introduce Karlin and Altschul algorithm
- describe BLAST programs
- introduce Gapped BLAST
- describe ALIGN program
- introduce PAM 120 weight residue table
- describe functional definition of oligonucleotide
- introduce hybridization conditions
- describe calculation of melting temperature
- introduce administration of therapeutic agent
- describe formulation of therapeutic agent
- introduce pharmaceutical compositions
- describe administration routes
- introduce aerosol formulations
- describe pharmaceutical carriers
- introduce viscoelastic gel formulations
- describe administration with tight junction disruptors
- introduce total amount of therapeutic agent
- describe oral administration
- introduce injectable and infusible solutions
- describe topical administration

### Example 1

- introduce cystic fibrosis disease
- describe ΔF508-CFTR mutation
- motivate search for interventions to rescue ΔF508-CFTR maturation and function
- introduce miR-138 and SIN3A gene network
- describe RNA isolation protocol
- describe oligonucleotide transfections protocol
- describe oligonucleotide reagents design and synthesis
- describe quantitative RT-PCR protocol
- describe electrophysiology studies protocol
- describe SDS-PAGE and immunoblotting protocol
- describe CFTR ubiquitination measurements protocol
- describe immunoprecipitation protocol
- describe measuring cell surface display of CFTR protocol
- describe pulse-chase live-cells surface ELISA protocol
- describe LDH cytotoxicity assay protocol
- describe experimental design
- fix and stain epithelial sheets
- perform statistical analysis
- summarize RNAi screen results
- identify candidate genes
- describe RNAi screen process
- analyze surface display of ΔF508-CFTR
- analyze maturation of ΔF508-CFTR
- analyze functional rescue of ΔF508-CFTR
- analyze NEDD8 expression in CF airways
- analyze effect of NEDD8 inhibition on ΔF508-CFTR
- analyze effect of SYVN1/NEDD8 knockdown on ΔF508-CFTR ubiquitination
- analyze effect of combining SYVN1/NEDD8 knockdown with C18 or low temperature
- analyze role of SYVN1 in ΔF508-CFTR ubiquitination
- analyze effect of inhibiting SYVN1 and NEDD8 expression on cAMP-dependent anion transport

## DISCUSSION

- show rescue phenotype of ΔF508-CFTR
- motivate SYVN1 as candidate gene
- describe SYVN1 inhibition effects on ΔF508-CFTR
- discuss SYVN1 role in ΔF508-CFTR degradation
- motivate NEDD8 as candidate gene
- describe NEDD8 knockdown effects on ΔF508-CFTR
- summarize SYVN1, FBXO2, and NEDD8 roles in ΔF508-CFTR regulation

